Radiology

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. Actinium Therapy For Late-stage Aggressive Sarcomas

   Rochester, Minn.

   The goal of this clinical trial is to learn about the safety of drug \[Ac225\]RTX-2358 and the diagnostic imaging agent \[Cu64\]LNTH-1363S. Additionally Ratio Therapeutics will learn if \[Ac225\]RTX-2358 drug is effective in treating advanced sarcoma.
   
   The main questions the study aims to answer in Phase/Part 1 of the trial are:
   
   * Is \[Ac225\]RTX-2358 tolerable or does it cause toxicities (medical problems) in patients.
   * What is the most tolerable dose of \[Ac225\]RTX-2358
   * Does the treatment show effectiveness on advanced sarcoma
   
   Participants will:
   
   * Take drug \[Ac225\]RTX-2358 once every 8 weeks (4 cycle target; 6 cycle maximum) over a period of 12 months
   * Visit the clinic three times for the first week of cycle one, then once a week for the remaining 7 weeks of cycle 1 for check-ups and tests.
   * For cycles 2-6: patient will visit the clinic once every 2 weeks for checkups and tests
   * Remain in long term follow-up for a period of four additional years

2. Assessment of the Mechanical Properties of Lung Parenchyma using Magnetic Resonance Elastography

   Rochester, Minn.

   The purpose of this research study is testing a new technique for measuring stiffness of the lung. This new technique is called Magnetic Resonance Elastography (MRE). In this study we will look at the stiffness measurements in humans.

3. A Study to Evaluate CHIP and Hematological Toxicity After PRRT in Neuroendocrine Tumor Patients

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The overall objective of this project is to combine robust clinical data (e.g. prior chemotherapy or radiation exposure, cumulative radiotheranostic dose) with geneticclonal abnormalities (blood-based CHIP panel) in studying the predisposing risk factors for developing hematological toxicity including t-MN in radiotheranostic treated solid tumor patients.

4. A Study to Evaluate Evacuation Mechanisms Using Advanced Brain Imaging

   Rochester, Minn.

   The objective of this study is to compare the central neural circuitry with fMRI (7T) in 30 asymptomatic healthy controls, 30 constipated patients without DD, and 30 constipated patients with DD at rest (functional connectivity analysis), during rectal distention to desire to defecate and urgency, and during evacuation. 

    

    

    

5. A Study of Change in Imaging Biomarkers of Dementia with Lewy Bodies (DLB) and Associations with Cognitive and Functional Decline

   Rochester, Minn., Jacksonville, Fla.

   Longitudinal Imaging Biomarkers of Disease Progression in Prodromal and Overt DLB

6. Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors

   Rochester, Minn.

   The purpose of this study is to evaluate the safety and effectiveness of using Exablate Model 4000 Type-2.0/2.1 in adults with Glioblastoma brain tumors to increase temporarily the permeability of the blood brain barrier, allowing increased passage of circulating free DNA (cfDNA) for sampling and analysis.

7. A Study to Evaluate Ultrasound Microvessel Imaging

   Rochester, Minn.

   The purpose of this study is to find out the optimal acquisition parameters for ultrasound microvessel imaging in healthy volunteers. 

8. MR Elastography of Hydrocephalus

   Rochester, Minn.

   We are doing this research study to develop and test the effectiveness of a new imaging technique called magnetic resonance elastography (MRE). This technique measures the stiffness (mechanical properties) of the brain and cerebral spinal fluid.

9. A Study of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction

   Jacksonville, Fla.

   The purpose of this study is to establish a registry that will address the data gap regarding the course of NSTEMI (Non-ST-Elevation Myocardial Infarction) between ED (Emergency Department) arrival and diagnostic angiography in detail, by characterizing and following the ED and peri-ED use of advanced OAP (Oral Anti-Platelet) agents. In addition to exploring ED treatment patterns and success of both ischemic and bleeding risk stratification prior to definition of the coronary anatomy, data generated via the UPSTREAM registry will allow plausible attribution of ischemic and bleeding outcomes to pre-catheterization antiplatelet therapy in the management of NSTEMI. This registry further seeks to demonstrate that contemporary use of upstream ticagrelor is associated with an economically-sound utilization of hospital resources, and smooth transition of care into the outpatient, secondary prevention setting for the first 30 days after hospitalization. Finally, it will allow characterization of patient selection factors and processes for ticagrelor vs alternative OAP agents, carrying out that descriptive comparison through discharge. Patients transferred in to an UPSTREAM hospital are eligible for inclusion, but the timing for OAP agent administration and diagnostic catheterization begin with ED care at the first hospital.

10. A Study to Evaluate Noninvasive Ultrasound Elastography of Kidney and Lung in Assessment of Volume Status in ICU Patients

    Rochester, Minn.

    The primary purpose of this study is to assess the feasibility of performing lung and kidney and lung ultrasound elastography among patients with critical illness from different etiologies that could be associated with volume overload.